Business ❯ Healthcare ❯ Pharmaceuticals

Market Trends

Novo Nordisk Revenue Growth Sales Performance Product Launches GLP-1 Drugs Company Valuation Obesity Treatment Weight-Loss Treatments Obesity Medications Obesity Drug Market Consumer Health Acquisitions Consumer Health Products Investment Strategies Vaccine Development Sales Projections Generic Products Revenue Projections Company Strategies Weight Loss Drugs Weight Management Next-Generation Therapies Weight-loss Drugs Industry Challenges Insulin Products COVID-19 Impact Investor Relations Vaccine Industry Growth Predictions Pulmonary Arterial Hypertension Prescription Growth Corporate Health Initiatives Obesity Drug Market Growth Eli Lilly Growth Stocks Oral GLP-1 Treatments Market Growth Investment Opportunities

Lilly Pulls Ahead in GLP‑1 Market as Novo Confronts U.S. Headwinds

Investor bets plus Lilly's oral pill Foundayo, factory expansion, larger R&D outlays have created a wide valuation gap that leaves Novo's recovery dependent on its pipeline and global reach.

Lilly Still Dominates GLP‑1 Market as New Rivals Gain Traction

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

Pfizer CFO Dave Denton to Exit and Cecile Guegan Named Interim

Nuvation Bio Reports Q1 Growth as Iptrozy Moves Earlier in ROS1 Lung Cancer Care

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

Novo Nordisk Strikes Hims & Hers Deal for Ozempic and Wegovy, Drops Patent Suit

Sanofi Replaces Paul Hudson, Names Belén Garijo as Next CEO

HSBC Upgrades AbbVie to Buy, Lifts Target to $265 as Skyrizi and Rinvoq Drive Growth

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Eli Lilly Briefly Hits $1 Trillion, First Drugmaker to Reach the Milestone